Washington University School of Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Washington University School of Medicine sits in the top decile of US sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count).

1,502 total trials 214 currently recruiting 919 completed early-phase tilt top decile by trial count

Washington University School of Medicine: 1,502 sponsored US clinical trials, 214 recruiting.

Washington University School of Medicine sponsors 1,502 registered US clinical trials on ClinicalTrials.gov, 214 of them currently recruiting, and 919 completed. 98 of these trials are in Phase 3-4 (later-stage) and 569 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 20 trials.

Top-decile sponsor footprint

Washington University School of Medicine ranks in the top decile of sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 38/100

919 of 1,159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,502 total, page 20 of 31

COMPLETED

EMA-Defined Tinnitus Subgroups

NCT02191592

COMPLETED Phase 4

Clinical Study of Generic and Brand Bupropion in Depression

NCT02209597

COMPLETED Phase 1

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

NCT02101034

COMPLETED NA

Reduction of Excessive Calories From Beverages in Children

NCT02239653

COMPLETED NA

Short Term Intermittent Fasting and Mediterranean Diet

NCT02148458

COMPLETED Early Phase 1

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT02117115

TERMINATED Phase 1

Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery

NCT02112162

TERMINATED NA

Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial

NCT02137200

COMPLETED Phase 1

Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer

NCT02172846

COMPLETED Phase 2

Omega-3 for Depression and Other Cardiac Risk Factors - 2

NCT02021669

COMPLETED Early Phase 1

Assessing NOS Uptake With PET Imaging in Lung Inflammation

NCT02151552

COMPLETED NA

Health Literacy Intervention for Informed Consent of Cancer Patients Considering Clinical Trial Participation

NCT01964222

COMPLETED NA

Effect of Skipping Breakfast on Metabolic Function

NCT02093572

COMPLETED Phase 2

Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy

NCT02167217

COMPLETED

Tumor: Breast Ratio Study

NCT02216136

COMPLETED NA

Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer

NCT02076074

COMPLETED Phase 2

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

NCT01969435

COMPLETED Phase 2

Tranexamic Acid Dosing in Adult Spinal Deformity Surgery

NCT02053363

COMPLETED Phase 2

Autologous Fecal Therapy

NCT02046525

COMPLETED

Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome

NCT02122666

TERMINATED

Diabetes and Glycosylation in Cervical Spondylosis

NCT02758899

TERMINATED Phase 1

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02057770

TERMINATED Phase 2

Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy

NCT01986829

COMPLETED Phase 3

The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

NCT01690988

COMPLETED

Immune Characterization of Subcutaneous Adipose Tissue

NCT02076087

COMPLETED Early Phase 1

Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma

NCT02316795

COMPLETED Early Phase 1

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

NCT02065609

COMPLETED NA

Calorie Restriction in Multiple Sclerosis Patients

NCT02411838

TERMINATED

PET Assessment of Acute Lung Transplant Rejection

NCT02204202

TERMINATED NA

Bone Marrow Aspirate Concentration in Posterior Cervical Fusion

NCT02068547

TERMINATED

Monitoring Brain Perfusion and Cerebral Oximetry in Carotid Endarterectomy Surgeries

NCT02102386

COMPLETED NA

Spinal Control During Functional Activities to Improve Low Back Pain Outcomes

NCT02027623

COMPLETED NA

A Randomized Controlled Trial of PCIT-ED for Preschool Depression

NCT02076425

TERMINATED Phase 1

Medication Enhanced Rapid Therapy

NCT02099825

COMPLETED

Assessing Change in Patient-reported Quality of Life After Elective Surgery: an Observational Comparison Study

NCT02771964

COMPLETED Phase 3

Age of Blood in Children in Pediatric Intensive Care Units

NCT01977547

COMPLETED Phase 4

Probiotics to Promote Intestinal Health

NCT02046512

TERMINATED Phase 1

Proton Beam Therapy to Treat Esophageal Cancer

NCT02023541

TERMINATED NA

Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial

NCT02315404

TERMINATED Phase 1

Imaging and Plan Workflow in a Novel Low-Field Magnetic Resonance Imaging (MRI) Radiotherapy Device

NCT02331381

TERMINATED Phase 2

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

NCT01779050

COMPLETED

Registry for Proton Beam Radiation Therapy

NCT02040467

COMPLETED NA

Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction

NCT02063217

COMPLETED

CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease

NCT02021682

COMPLETED NA

Protein Intake & Insulin Action

NCT02004002

COMPLETED Phase 1

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

NCT01913951

COMPLETED Phase 2

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

NCT01928290

COMPLETED NA

CYP2B6 Polymorphisms in Ketamine

NCT01988922

COMPLETED

Diagnosis of Bile Duct Strictures

NCT02000999

COMPLETED Early Phase 1

Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide

NCT01907165

← Previous Page 20 of 31 Next →

Phase Distribution

PhaseTrial count
Phase 1 332
Phase 2 237
Phase 3 40
Phase 4 58

What is open in the Washington University School of Medicine pipeline

214 recruiting of 1,502 indexed (14% open); 919 completed (61%).

Phase mix: 98 late (III/IV) vs 569 early (I/II) (early-phase heavy).

Top condition: Obesity (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Washington University School of Medicine: open-pipeline peers nationwide

Peers matched on 1,502 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Washington University School of MedicineYale UniversityJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,502 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Washington University School of Medicine page

1,502 registered trials is a research-attention snapshot, not an endorsement of Washington University School of Medicine or any single study.

  • 214 of Washington University School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Washington University School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Washington University School of Medicine pipeline card: 1,502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.